Type 2 diabetes mellitus: Issues for the medical care of pediatric and adult patients

Southern Medical Journal

Volumn 95, Issue 9, 2002, Pages 992-1000

  Beck, Michael J ^a   Evans, Barbara J ^a   Quarry Horn, Jill L ^a   Kerrigan, James R ^a  

^a PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; ANTIDIABETIC AGENT; BIGUANIDE DERIVATIVE; INSULIN; METFORMIN; PIOGLITAZONE; REPAGLINIDE; ROSIGLITAZONE; SULFONYLUREA DERIVATIVE; THIAZOLIDINE DERIVATIVE;

ADULT; ADULT DISEASE; ALGORITHM; CHILD; CHILDHOOD DISEASE; DIABETES CONTROL; DRUG MECHANISM; EXERCISE; HUMAN; INCIDENCE; MEDICAL CARE; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOGENESIS; REVIEW; SCREENING; SYMPTOMATOLOGY; TREATMENT OUTCOME; TREATMENT PLANNING;

EID: 0036732970     PISSN: 00384348     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007611-200209000-00012     Document Type: Review

References (45)

1. Reduction in the incidence of type 2 diabetes with lifestyle intervention or mefformin
2. Type 2 diabetes in children and adolescents
3. ACE guidelines for glycemic control
4. Pharmacologic therapy for type 2 diabetes mellitus
5. Genetic and environmental determination of type II diabetes in Mexico City and San Antonio
6. Fasting hyperglycemia in non-insulin dependent diabetes mellitus: Contributions of excessive hepatic glucose production and impaired tissue glucose uptake
7. Pathogenesis of type 2 diabetes: Metabolic and molecular implications for identifying diabetes genes
8. Contribution of abnormal muscle and liver glucose metabolism to postprandial hyperglycemia in NIDDM
9. The disposal of an oral glucose load in patients with non-insulin dependent diabetes
10. Beta-cell dysfunction and failure in type 2 diabetes: Potential mechanisms
11. Clinical practice recommendations 2002
12. ACE consensus conference on guidelines for glycemic control
13. Screening for type 2 diabetes
14. Screening and diagnostic testing for diabetes and related conditions
15. Report of the expert committee on the diagnosis and classification of diabetes mellitus
16. Coronary-heart disease risk and impaired glucose tolerance: The Whitehall study
17. The prevention or delay of type 2 diabetes
18. Guidelines for healthy weight
19. Effect of metformin in pediatric patients with type 2 diabetes: A randomized control trial
20. Efficacy, safety, and dose-response characteristics of glipizide gastrointestinal therapeutic system on glycemic control and insulin secretion in NIDDM. Results of two multicenter, randomized, placebo-controlled clinical trials, the Glipizide Gastrointestinal Therapeutic System Study Group
21. Glimeperide, a new once-daily sulfonylurea, a double-blind placebo-controlled study of NIDDM patients
22. Sulfonylureas in NIDDM
23. Comparison of pharmacokinetics, metabolic effects and mechanisms of action of glyburide and glipizide during long-term treatment
24. Effect on glipizide on postprandial lipaemia in patients with NIDDM
25. PPAR-γ:adipogenic regulator and thiazolinedione receptor
26. Metabolic effects of troglitazone monotherapy in type 2 diabetes mellitus, a randomized, double-blind placebo-controlled trial
27. Acarbose. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential
28. A new oral therapy for diabetes management: Alpha-glucosidase inhibition with acarbose
29. Comparative tolerability profiles of oral antidiabetic agents
30. The efficacy of acarbose in the treatment of patients with non-insulin dependent diabetes mellitus, a multicenter controlled clinical trial
31. Reduction of glycosylated hemoglobin and postprandial hyperglycemia by acarbose in patients with NIDDM. A placebo-controlled dose comparison study
32. The effects of the α-glucose inhibitor BAY g 5421 (acarbose) on meal-stimulated elevations of circulating glucose, insulin, and triglyceride levels in man
33. A comparison of acarbose versus metformin as an adjuvant therapy in sulfonylurea-treated NIDDM patients
34. Recent developments in the pharmacological reduction of blood glucose in patients with type 2 diabetes
35. Hyperglycemia and microvascular and macrovascular disease in diabetes care
36. Pathogenesis of type 2 diabetes, prevalence and causes of albuminuria in noninsulin diabetic patients
37. Histopathological heterogeneity of neuropathy in insulin-dependent and noninsulin-dependent diabetes, and demonstration of axo-glial dysfunction in human diabetic neuropathy
38. Impact of initial treatment on renal function in newly diagnosed type 2 (noninsulin-dependent) diabetes mellitus
39. Inferences and implications. Do results from the Diabetes Control and Complications Trial apply in NIDDM?
40. Implications of the United Kingdom Prospective Diabetes study
41. Comparison of tests for glycated haemoglobin and fasting and two hour plasma glucose concentrations as diagnostic methods for diabetes
42. 1c levels for diagnosing diabetes: Diagnostic criteria and performance revisited
43. Long-term complications of diabetes mellitus
44. Effects of intensive blood-pressure lowering and low-dose aspirin on patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomized trial